Format

Send to

Choose Destination
J Immunol Res. 2015;2015:595363. doi: 10.1155/2015/595363. Epub 2015 Dec 30.

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.

Author information

1
Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany; Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany.
2
TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
3
Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany; Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany; TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.

Abstract

Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).

PMID:
26844233
PMCID:
PMC4710911
DOI:
10.1155/2015/595363
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center